Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05630755 · ClinicalTrials.gov registry record · Phase 3
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
A Phase 3 study of HIV-1-infection, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 514
- Enrollment target
- 20
- Study locations
NCT05630755 is a Phase 3 study of HIV-1-infection that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 514 participants, above the 344-participant average among 71 other HIV-1-infection trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT05630755, a Phase 3 study of HIV-1-infection, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 514 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) at Week 48; and to evaluate the safety and tolerability of a switch to DOR/ISL compared with continued BIC/FTC/TAF, through Week 48. The primary hypotheses are that (1) DOR/ISL is non-inferior to continued BIC/FTC/TAF, as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48, with a margin of 4 percentage points used to define non-inferiority; and (2) DOR/ISL is superior to BIC/FTC/TAF, as assessed by the percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48.
Conditions Studied
Interventions
- DRUG BIC/FTC/TAF
- DRUG DOR/ISL
- DRUG Placebo to BIC/FTC/TAF
- DRUG Placebo to DOR/ISL
Study Locations (20)
Florida
- Therafirst Medical Center ( Site 1402) - Fort Lauderdale
- Midway Immunology and Research Center ( Site 1401) - Ft. Pierce
- AHF The Kinder Medical Group ( Site 1426) - Miami
- Orlando Immunology Center ( Site 1407) - Orlando
- Triple O Research Institute, P.A ( Site 1417) - West Palm Beach
California
- Pacific Oaks Medical Group ( Site 1400) - Beverly Hills
- Ruane Clinical Research Group, Inc ( Site 1414) - Los Angeles
- Mills Clinical Research ( Site 1433) - Los Angeles
Texas
- Central Texas Clinical Research ( Site 1413) - Austin
- St Hope Foundation ( Site 1410) - Bellaire
- Prism Health North Texas, Oak Cliff Health Center ( Site 1409) - Dallas
Georgia
- Infectious Disease Specialists of Atlanta ( Site 1403) - Decatur
- Mercer University, Department of Internal Medicine ( Site 1411) - Macon
Arizona
- Pueblo Family Physicians ( Site 1425) - Phoenix
District of Columbia
- Whitman-Walker Institute ( Site 1431) - Washington D.C.
Massachusetts
- AccessHealth MA ( Site 1419) - Boston
Michigan
- Be Well Medical Center ( Site 1408) - Berkley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2023-02-17 |
| Est. Completion | 2028-08-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05630755
The ClinicalTrials.gov registry entry for NCT05630755 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 514 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 344-participant average among 71 other HIV-1-infection trials with a reported enrollment target (49% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 4 interventions - of which BIC/FTC/TAF is the first listed.
NCT05630755 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT05630755 about?
NCT05630755 is a clinical study titled "A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)". The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) at Week 48; and to evaluate the safety and tolerability of a switch to DOR/ISL compare...
What is the current status of trial NCT05630755?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 514 participants. The study started on 2023-02-17. Estimated completion is 2028-08-04.
What conditions does trial NCT05630755 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT05630755?
The interventions under investigation include: BIC/FTC/TAF (DRUG), DOR/ISL (DRUG), Placebo to BIC/FTC/TAF (DRUG), Placebo to DOR/ISL (DRUG).
Who is sponsoring clinical trial NCT05630755?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05630755 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
ACTIVE NOT RECRUITING · Phase 3
-
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
ACTIVE NOT RECRUITING · Phase 3
-
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
ACTIVE NOT RECRUITING · Phase 3
-
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
ACTIVE NOT RECRUITING · Phase 3
-
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.